More Evidence that Walking is Good for the Brain

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

For the second time in as many months, a major study has shown that a regular walk leads to better brain health.

We recently posted this analysis of data from the Cardiovascular Health Study - Cognition Study showing that regular walking over a period of years preserved brain volume. Now, further analysis of the same data set was presented at the Radiological Society of North America showing that cognition was preserved among walkers at a significantly better level than among a sedentary group.

The data are compelling; a regular daily walk is good for you.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Promising Alzheimer's Drugs on the Horizon

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

While we often emphasize the importance of non-pharmacologic therapies for treating Alzheimer's disease, more effective drugs could have an enormous, positive impact on our ability to combat its looming threat. A such, here is a brief summary of three of the most promising treatments in the FDA pipeline.

All three of these agents operate on the amyloid hypothesis which holds that, an accumulation of beta-amyloid, a naturally occurring protein in the brain, is the cause of Alzheimer's disease. While two recent trials on agents developed to reduce the production of beta-amyloid have failed, these three are intended to remove beta-amyloid from the brain.

Two similar drugs are Solanezumab and Bapineuzumab. Both are anti-bodies that attach to amyloid and then carry it away when they are flushed out of the body by the immune system. Solanezumab most likely operates outside of the brain which may lead to better tolerance than Bapineuzumab, which had more evidence of efficacy in its earlier stage studies. Each trial is well underway and the first published data should be forthcoming in late 2011 or early 2012.

Gammagard is Baxter's intraveneous immunoglobulin or IVIG, which also relies on removing amyloid through immune system mechanisms. IVIG is already on the market but with no approved claims for treating Alzheimer's disease.

There are certainly other approaches in the pipeline, some of which may bring better results in a shorter time frame than the three highlighted here. But these seem to have the strongest theoretical underpinnings and have bred the most optimism in the scientific community.
-------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.

Treating Alzheimer's Disease Without Drugs

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

One of the common themes in this blog is that "current treatment for Alzheimer's disease is better than many headlines indicate".

We write this because the argument against treatment efficacy is almost always framed through the narrow lens of drug-based interventions when, in reality, drugs are only one part of the most effective approach. A robust approach includes management of risk factors like smoking and excessive drinking, controlling co-morbid conditions such as diabetes and hypertension, proper diet, physical exercise, and both social and intellectual engagement.

We also point out that many reports of poor treatment efficacy are based on studies of Alzheimer's patients in whom the disease is too far progressed, and the brain too ravaged, for treatment to have a fair chance at working.

There is an additional area of treatment that has shown impressive efficacy and should be emphasized as well; it is psychosocial interventions. These include care-giver education, structured communication techniques, home safety, family counseling, and problem resolution. The results have been clear; caregivers who know what to expect and how best to deal with problems as they emerge, are less stressed, less depressed, and more effective in giving care. The result is healthier patients who maintain higher quality of life and a prolonged ability to avoid institutionalized care.

The Huffington Post has a great summary today of this approach and I encourage all readers to click through and to share this with their interested peers.
--------------------------------------------------------------------------------
A better understanding and more awareness of Alzheimer's related issues can impact personal health decisions and generate significant impact across a population of aging individuals. Please use the share buttons below to spread this educational message as widely as possible.